Dr. Adam Antebi is an Assistant Professor at Baylor College of Medicine, Huffington Center on Aging, Department of Molecular and Cellular Biology, Houston, studying endocrine regulation of C. elegans development and aging. Previously, he was an independent group leader at the Max-Planck Institute for Molecular Genetics, Berlin, a post-doctoral fellow with Dr. Edward Hedgecock at Johns Hopkins University, Baltimore, and a doctoral student with Dr. Gerald Fink at the Massachusetts Institute for Technology, Cambridge. He has been awarded the Beinecke Graduate Fellowship, Damon Runyon-Walter Winchell and NIH post-doctoral fellowships, an EU grant and National Genome Research Grant for his research at the Max-Planck. Recently, he received the Glenn/AFAR Breakthroughs in Gerontology Award and a grant from the Nuclear Receptor Signaling Atlas (NIH). He has also served on the advisory boards of the Wellcome Trust Initiative for Functional Genomics of Aging and the Max Planck Initiative on Gerontology.
Dr Roland Baron is a Professor in the departments of Orthopedics and Cell Biology at Yale University School of Medicine, where he has been since 1977. He received his DDS and PhD degrees from the University of Paris, France. He is the founder and current Editor-in-Chief of BONE, the Official Journal of the International Bone and Mineral Society. Between 1994 and 2002, he has also held the position of Vice President and Head of the Bone Diseases Group at Hoechst Marion Roussel and then Aventis. In 2002 he founded ProSkelia, a small pharmaceutical company devoted to the discovery and development of new drugs for bone and hormonal dependent diseases. He has held the positions of President and Chief Scientific Officer of ProSkelia and then ProStrakan, a merger between ProSkelia and Strakan, until April 2006. Dr Baron has published over 240 scientific papers in the field of bone cell and molecular biology.
Nick Bishop has been Professor of Paediatric Bone Disease in Sheffield since 1998, having trained in Manchester and Cambridge UK, and Montreal, Canada. His main research interests are treatment strategies in osteogenesis imperfecta and other causes of osteoporosis and recurrent fractures in children, and osteoclast formation defects leading to osteoclast-poor osteopetrosis.
Matt Brown is a clinician-scientist who trained initially in medicine and rheumatology in Sydney, Australia before moving in 1994 to Oxford, England. Working at the Wellcome Trust Centre for Human Genetics and the Botnar Research Centre (University of Oxford Institute of Musculoskeletal Sciences), he pursued gene-mapping and genetic epidemiology studies in musculoskeletal diseases, including ankylosing spondylitis, rheumatoid arthritis, chondrocalcinosis and osteoporosis. He was appointed Professor of Musculoskeletal Sciences at University of Oxford in 2004.
In 2005 Matt returned to Australia, taking a chair of immunogenetics at University of Queensland, based at the Centre for Immunology and Cancer Research in Brisbane. There he continues to work in musculoskeletal genetics, both in humans and in mouse models of ankylosing spondylitis and chondrocalcinosis.
Cyrus Cooper is Professor of Rheumatology and Director of the MRC Epidemiology
Resource Centre at the University of Southampton Medical School and Southampton
General Hospital in the UK. Professor Cooper graduated from the University
of Cambridge and St Bartholomew’s Hospital, London in 1980, and
completed his residency in 1985 at the Southampton University Hospitals.
He then worked in the MRC Environmental Epidemiology Unit as an MRC Training
Fellow, and at the University of Bristol as a Senior Registrar in Rheumatology.
In 1990, he won an MRC Travelling Fellowship to the Mayo Clinic, USA,
where he continued his research in osteoporosis. Cyrus Cooper returned
to the UK in 1992 to take up a position as Senior Lecturer in Rheumatology
and MRC Senior Clinical Scientist. He was promoted to the foundation
Chair in Rheumatology at the University of Southampton in 1997 while
continuing as an MRC Senior Clinical Scientist at the MRC Environmental
Epidemiology Unit. In 2003, he was appointed Director of the MRC Epidemiology
Resource Centre, University of Southampton.
Professor Steven R. Cummings trained in internal medicine and was Chief of General Internal Medicine at UC San Francisco for a decade. As the clinical consultant in Postmenopausal Health for UC San Francisco, he cared for women who had special issues in osteoporosis, hormone therapy, and other concerns. He teaches and coauthors a textbook about how to design and conduct clinical research. As founder and director of the S.F. Coordinating Center, he has led large studies about BMD, risk factors, and and fractures in women (the Study of Osteoporotic Fractures) and in men (the Mr.Os study). He has played a leading role in several major fracture prevention trials involving alendronate, raloxifene, estrogen therapy, and new agents (lasofoxiene, AMG 162, and tibolone). He has served on the Boards of IOF and NOF. Professor Cummings is skeptical about common dogmas.
Following his period at the National Cancer Institute, during which he was involved in projects concerning the role of cytokines in the differentiation of tumor cells, dr. De Benedetti has focused his research on the role of inflammatory cytokines in pediatric chronic inflammatory diseases with particular interest on interleukin-6.
Pierre De Meyts studied medicine at the University of Liège in Belgium, where he graduated in 1969. After three years of specialization in Internal Medicine, Diabetes and Endocrinology, he joined in 1973 the group of Jesse Roth at the NIH in Bethesda, MD, USA, where he started work on the insulin receptor. In 1975, he won the Solomon A. Berson Research and Development Award from the American Diabetes Association. In 1976, he joined the International Institute of Cellular and Molecular Pathology in Brussels recently founded by Nobel Laureate Christian de Duve. De Meyts won the Belgian Alumni Prize in 1978 and shared the Diaz Cristobal Prize from the Spanish Diabetes Association with his former mentor Jesse Roth at the IDF Congress in Vienna in 1979. In 1981, De Meyts won the Oskar Minkowski Prize from the European Association for the Study of Diabetes.
In 1986, he became Director of the Department of Diabetes, Endocrinology and Metabolism and Associate Director of the Department of Molecular Genetics at the City of Hope National Medical Center and Beckman Research Institute in Duarte, California. He was also appointed Clinical Professor of Medicine at the University of Southern California.
In 1990, De Meyts moved to Denmark to become Director of Research of the Hagedorn Research Institute in Gentofte, a position he held until May 2000. He is currently Scientific Director of the Receptor Biology Laboratory, an independent basic research component of Novo Nordisk R&D hosted at the Hagedorn Research Institute. In 1995, he obtained the degree of "Agrégé de l’Enseignement Supérieur" (Ph.D) at the Catholic University of Louvain in Belgium, where he teaches part-time as a Professor in the Department of Chemistry. From 2000-2005, he was also Adjunct Professor of Experimental Endocrinology in the Faculty of Health Sciences at Copenhagen University. He won in 1995 the Quinquennial Prize Joseph Maisin of the Belgian National Fund for Scientific Research for the Biomedical Sciences and in 2002 the Belgian Christoffel Plantin Prize.
He is member of numerous scientific societies and has served on the editorial board of several scientific journals including Endocrinology and the Journal of Biological Chemistry. He has authored more than 150 papers, mostly on polypeptide hormone receptors and mechanism of action, especially on insulin, growth hormone and insulin-like growth factors. De Meyts received in May 2005 the Frontiers in Science award from the American Association of Clinical Endocrinologists.
Henry J. Donahue is the Michael and Myrtle Baker Professor and Director of the Division of Musculoskeletal Sciences in the Department of Orthopaedics and Rehabilitation at the Pennsylvania State University College of Medicine. His laboratory group focuses on intercellular communication and mechano-transduction in bone, cancer metastasis, functional tissue engineering and regenerative medicine as it applies to the musculoskeletal system and the application of nanotechnology to bone regeneration.
Paul Emery is arc Professor of Rheumatology and Head of Academic Unit of MSKD at the University of Leeds. He is Clinical Director (Rheumatology) at the Leeds Teaching Hospitals Trust in the United Kingdom.
Professor Emery graduated in medicine from the University of Cambridge, and completed internal medicine and rheumatology at Guys, Head of Rheumatology Walter and Eliza Hall Institute in Melbourne, then SL University of Birmingham, UK. He is currently the Treasurer for EULAR, a past member of the Scientific Committee and Chairs the MRI imaging group. He serves on the editorial boards of several journals.
He is a recipient of the Roche Biennial Award of Clinical Rheumatology, the Rheumatology Hospital Doctor of the Year award 1999 and EULAR prize 2002 for outstanding contribution to Rheumatology research.
Professor Emery’s research interests centre around the immunopathogenesis and immunotherapy of rheumatoid arthritis and connective tissue diseases. He has a special interest in the factors leading to persistent inflammation. He has published over 450 peer reviewed articles in this area.”
Thomas A. Einhorn is Chairman of the Department of Orthopaedic Surgery and Professor of Orthopaedic Surgery, Biochemistry and Biomedical Engineering at Boston University. A graduate of Rutgers University and Cornell Medical College, he completed his internship at the Hospital of the University of Pennsylvania, orthopaedic residency at St. Luke's - Roosevelt Hospital in New York City, and a fellowship at the Hospital for Special Surgery. His professional interests include research on the repair and regeneration of bone and cartilage, reconstructive surgery of the hip and knee, and the treatment of metabolic bone disease.
He has served as Chairman of the Orthopaedics and Musculoskeletal Study Section of the National Institutes of Health, President of the Orthopaedic Research Society, President of the International Society for Fracture Repair and Chairman of both the Committee on Examinations and the Council on Research and Scientific Affairs of the American Academy of Orthopaedic Surgeons.
Currently, he serves on the Board of Trustees of the Orthopaedic Research and Education Foundation and the National Osteoporosis Foundation. His awards include the American British Canadian Traveling Fellowship, Marshall R. Urist Award, and Kappa Delta Award. He is Deputy Editor for Current Concepts Reviews for The Journal of Bone and Joint Surgery, and serves on the Editorial Boards of The Journal of Bone and Mineral Research, Journal or Orthopaedic Research and Bone. Since 1997, he has been listed in Best Doctors. An author of over 135 peer-reviewed articles, his career goals are dedicated to exploring the role of molecular medicine in orthopaedic surgery.
Beverley Fermor is currently Assistant Research Professor in the Division of Orthopaedics, Department of Surgery at Duke University, USA. She obtained her Ph.D in Cancer research from the University of Bristol, England. She then did post-doctoral training with Tim Skerry in the Department of Anatomy, University of Bristol on the effects of mechanical loading on bone, using the rat ulna model. She then moved to the Nuffield Orthopaedic Center, University of Oxford to work with David Murray, developing in vitro systems to apply mechanical signals to bone. At Oxford she also collaborated with Jill Urban who stimulated her interest in articular cartilage. Beverley moved to Duke University in 1998, to continue working on mechanical loading of articular cartilage with Farshid Guilak. Her current interests include understanding the effects of environmental factors, such as mechanical loading and oxygen tension, on articular cartilage.
Serge L Ferrari is currently a Swiss National Science Foundation granted Professor of Medicine at the Service of Bone Diseases, Geneva University Hospital, Switzerland. His research in Geneva and with collaborators at Harvard Med School focuses on the genetics of osteoporosis as well as on bone anabolic pathways, particularly PTH signaling. He is member of the Board of Directors of the Swiss Bone and Mineral Society and of the Board of Directors of the International Society of Nutrigenetics and Nutrigenomics, a member of the editorial board of the Journal of Bone and Mineral Research and Osteoporosis International, and an associate editor for Bone Key. He serves as a genetics consultant among the Framingham Osteoporosis Study Investigators. He has received numerous international awards for his work, including from the American Society for Bone and Mineral Research, and published more than 80 articles and book chapters on bone mass aquisition in childhood, osteoporosis and bone and mineral metabolism.
Patrick Garnero is Vice President of Molecular Markers of Synarc and senior research scientist at the French Institute for Medical Research (INSERM) in Lyon, France. Dr. Garnero received a Ph.D. in Human Biology and Biochemistry from the University of Lyon, France. He did his postdoctoral training at the Division of Bone Diseases at Hôpital Cantonal in Geneva, Switzerland and at the Center for Clinical and Basic Research in Copenhagen, Denmark.
Dr Garnero is an active researcher in the field of metabolic bone diseases with special focus on osteoporosis and osteoarthritis. He is an internationally-recognized leader in the field of bone and cartilage biochemical markers. Dr Garnero authored more than 200 articles and book chapters in international scientific journals. He is a member of the American Society for Bone and Mineral Research and of the American College of Rheumatology. He serves on a numerous standardization committees and expert panels under the auspices of the NIH, NCCLS and CDC to advance biochemical markers in clinical research.
Dr. Theresa A. Guise is the Gerald D. Aurbach Professor of Endocrinology, Mellon Investigator and Director of the Osteoporosis and Metabolic Bone Disease Clinic at the University of Virginia. She directs a clinical and basic research program in metabolic bone diseases with an emphasis on skeletal complications of malignancy.
She received her M.D. from the University of Pittsburgh School of Medicine in 1985 and completed an internal medicine residency there from 1985 to 1988. A fellowship in endocrinology and metabolism followed at the University of Texas from 1989-1992. She served on the faculty in the Division of Endocrinology, Department of Medicine, at the University of Texas Health Science Center at San Antonio from 1992-2002. She also served as Zachary Chair for Translational Research at the Institute for Drug Development of the Cancer Therapy and Research Center. Dr. Guise received the Fuller Albright Award from the American Society of Bone and Mineral Research in 1999, as well as the Outstanding Investigator Award from the International Bone and Calcium Institute. She served as Co-Chair of the Scientific Meeting for the American Society of Bone and Mineral Research for 2002. Editorial board service includes the Journal of Clinical Endocrinology and Metabolism, Endocrinology and BoneKEy, a publication of the International Bone and Mineral Society. She is a reviewer for 15 other journals, including Journal of Clinical Investigation, Cancer Research, Endocrinology, New England Journal of Medicine and Bone. She is on the Board of Directors for the Paget Foundation for Bone Diseases, the International Bone and Mineral Society and the Council of the American Society for Bone and Mineral Research.
Dr. Guise’s principal laboratory interests encompass skeletal complications of malignancy: tumor metastasis to bone and the effect of cancer treatment on skeletal health. Specifically, she studies the molecular mechanisms by which tumor cells interact with bone cells to cause either bone destruction (osteolytic metastases) or new bone formation (osteoblastic metastases) using mouse models. The effect of cancer treatments, such as androgen deprivation for prostate cancer and aromatase inhibitors for breast cancer, on bone mass as well as the development and progression of bone metastasis is under investigation. In these areas, she is currently involved as principal investigator in several grant-funded research projects from the NIH and the Department of Defense
Dr. Guise’s clinical interests encompass diseases of calcium and bone metabolism, and she is Principal Investigator on several clinical trials. She was elected to the American Society for Clinical Investigation in 2004 and is a permanent member of the NIH study section of Skeletal Biology, Structure and Regeneration.
1975 Highschool degree in Berlin
Howy Jacobs leads a research group at the Institute of Medical Technology (IMT) of the University of Tampere, Finland, studying various aspects of mitochondrial biogenesis in relation to human disease and ageing. After graduating from Cambridge he did his PhD work in Glasgow, Scotland, was then a postdoc in Caltech before returning to Glasgow to set up his own group in the mid-1980s. He moved to IMT in 1996, and has since then been highly active in a number of pan-Europoean collaborations to develop an understanding of mitochondrial disease at the molecular level and help devise a feasible strategy for therapy. Since 2001 he is a member of EMBO, and was also a former Honorary Secretary of the UK Genetics Society.
Moustapha Kassem received his medical degree from the University of Cairo, Egypt (1985), PhD (1993) and DSc (1997) from the University of Aarhus, Denmark. He has had a post-doctoral fellowship at the Mayo Clinic, Rochester, MN, USA. Since 2002, he has been appointed as professor of Endocrinology and consultant Endocrinologist at the University Hospital of Odense, Odense, Denmark and director of the Laboratory of the Molecular Endocrinology at the Medical Biotechnology Centre, University of Southern Denmark, Odense, Denmark (www.mbc.sdu.dk). Dr. Kassem research focuses on the cellular and molecular mechanisms of osteoblast differentiation from stem cells and how these processes are affected by aging and osteoporosis. He has published more than 70 original papers in international peer-review journals including Nature and Science. He has also published more than 30 reviews and book chapters.
Sundeep Khosla is Professor of Medicine and Associate Director for Research at the Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Dr. Khosla received his undergraduate degree from Harvard College and his M.D. from Harvard Medical School. He subsequently completed residency and fellowship training at the Massachusetts General Hospital, with the research component of his fellowship in Dr. Henry Kronenberg's laboratory. Dr. Khosla's clinical and research interests are in osteoporosis and the actions of sex steroids on bone. He has published extensively in these areas and has received numerous awards and honors for his work. He is a member of the American Society for Clinical Investigation, a past Council Member of the ASBMR, and Vice-President of the National Osteoporosis Foundation.
David Kipling did a BA at Cambridge (Natural Sciences), DPhil at Oxford, then postdoctoral work in Edinburgh, before moving to Cardiff in 1997. He currently has a Personal Chair in the School of Medicine at Cardiff University. His group is interested in the basic biology of human ageing, and in a particular the issue of how cells count division, how the special DNA at the ends of our chromosomes (telomeres) are involved in this process, and how this relates to the mechanism of accelerated ageing that is seen in Werner's syndrome. He is one of the Academic Co-ordinators of the BBSRC Science of Ageing (SAGE) and Experimental Research on Ageing (ERA) special funding initiatives, a panel member for the BBSRC/EPSRC SPARC initiative, and was until recently Honorary General Secretary of the British Society for Research on Ageing.
Thorsten Kirsch performed his PhD work at the Max-Planck Society Clinical Research Units for Rheumatology in Erlangen, Germany and received his PhD degree in 1992 from the Friedrich-Alexander University, Erlangen with summa cum laude. He did his postdoctoral training at the University of South Carolina and the University of Pennsylvania, USA. In 1999 he was appointed to Research Assistant Professor at the University of Pennsylvania, School of Dental Medicine. In 2000 he was appointed Assistant Professor in the Department of Orthopaedics & Rehabilitation at Penn State College of Medicine in Hershey. Since 2002 Dr. Kirsch is Associate Professor and Director of Orthopaedic Research in the Department of Orthopaedics at the University of Maryland School of Medicine in Baltimore, MD.
Dr. Kirsch has published more than 45 articles in peer-reviewed journals and has received numerous awards, including the New Investigator Recognition Award from the Orthopaedic Research Society. Dr. Kirsch is a grant reviewer for various National Institutes of Health Study Sections.
Selected Recent Publications:
Craig B. Langman is the Isaac A. Abt, MD Professor of Kidney Diseases at the Feinberg School of Medicine, Northwestern University and Head of Kidney Diseases at Children’s Memorial Hospital, in Chicago, IL, USA. Dr. Langman is an internationally recognized scholar for his research that has focused on the basic and clinical expression of inherited or acquired disorders of bone metabolism in children.
Dr. Langman has published more than 160 articles, reviews, chapters, and commentaries. He serves as the Senior Associate Editor of the American Journal of Nephrology, Associate Editor for the Primer on the Metabolic Bone Diseases, Section-Editor on Hereditary/Tubular Diseases for Pediatric Nephrology, and on the Editorial Advisory Board of the Journal of Bone and Mineral Research. He served as chair for the 2005-released National Kidney Foundation K-DOQI guidelines on Pediatric Renal Osteodystrophy. Dr. Langman has the Mary Weston Professorship at the University of Natal, Durban South Africa, where he studies the role of genetics in the progression of chronic kidney diseases in children.
Dr. Langman’s most recent studies examine the effects that chronic kidney disease produces on the cardiovascular system and on the skeleton.
Lance Lanyon qualified as a veterinarian from the University of Bristol in 1966 where he was a faculty member until 1979. From 1979 to 1984 he worked at Tufts University in Boston before moving to the Royal Veterinary College in London. He was Principal of the RVC from 1989 to 2003 and is now Professor Emeritus.
During the research for his PhD he established the technique of successfully attaching gauges capable of measuring mechanical strains in bones during physical activity in vivo. Once functional bone strains could be measured the mechanism by which bone cells’ mechanical environment influences them to adjust bone architecture appropriately could be investigated directly. Recently his research has concentrated on the implications of the unexpected finding that the estrogen receptor has a role in bone cells’ early responses to strain, and that reduced effectiveness of mechanically adaptive bone remodelling post-menopausally may reflect reduced estrogen receptor function.
Dr Little graduated MBBS from the University of Sydney in 1986. After selection on the Australian Orthopaedic Association training scheme in 1990 Dr Little graduated FRACS(Orth) in 1994. He undertook fellowships in Paediatric Orthopaedics at the Shriners Hospital for Children in Portland, OR, USA and Texas Scottish Rite Hospital for Children in Dallas TX, USA.
Dr Little commenced on staff at the Children’s Hospital, Westmead, when it opened in November 1995. In 1998 he began researching the role of bisphosphonates in distraction osteogenesis and in 1999 officially founded Orthopaedic Research and Biotechnology at CHW. Dr Little remains Head of the Unit, and Deputy Head of the Department of Orthopaedics.
In 2002 Dr Little was an ABC travelling fellow, presenting his research with other international fellows from UK, NZ and Sth Africa on a six-week tour of North America. In 2005 Dr Little was awarded his PhD on bisphosphonates in distraction osteogenesis. He has initiated further research on osteonecrosis, fracture healing and the interaction of the anabolic and catabolic responses in bone repair.
Dr Little remains active clinically and is now working on translating pre-clinical work on bone healing to clinical practice.
Leif Mosekilde is professor in osteoporosis and metabolic bone diseases at Aarhus University and chief physician at the Division of Endocrinology and Metabolism, Aarhus University Hospital. His thesis on the “Effects of thyroid hormone(s) on bone remodeling, bone mass and calcium-phosphorus metabolism” was defended in 1978. Over the years he has published more then 300 original international papers on bone histomorphometry, calcium kinetics, bone strength, vitamin D metabolism, metabolic bone diseases and osteoporosis and pharmaco-epidemiology. He has also produced several invited reviews and textbook chapters. He has supervised 24 Ph.D. students and doctoral theses. He has been member of the National Committee for Clinical Education in Endocrinology, the Danish Nutritional Council, The National Strategy Committee for Health Research, and the Research Councils of the Danish Institute for Health Authorities. He is co-editor of Calcified Tissue Research and Journal of Bone and Mineral Research.
Dr. Robey received her Ph.D. in Cell Biology and Biochemistry from the Catholic University of America in 1979, and performed her post-doctoral training at the National Institutes of Health. She is currently Chief of the Craniofacial and Skeletal Diseases Branch in the National Institute of Dental and Craniofacial Research at NIH, and is an active member in a number of professional societies related to bone and dental research. Her studies have focused on the isolation and characterization of stem cells that form hard tissue, identification of the roles that they play in health and disease, and their use in regenerative medicine. Because of her expertise, she is a member of the NIH Stem Cell Task Force, and is frequently invited by schools and community groups to provide the last information in stem cell biology. Her favorite hobby is cooking, although as her daughter says “She doesn’t always follow the recipe…”
Professor Paul Sharpe is the Dickinson Professor of Craniofacial Biology at Kings College London and founder/scientific Director of Odontis Limited, a university spin-out company that specialises in tissue engineering of teeth. He graduated with a degree in biology from York University (1977) and a PhD in biochemistry from Sheffield University (1981). Following postdocs in Sheffield, Wisconsin and Cambridge he became lecturer in molecular embryology at the University of Manchester in 1987 where he established a research group working on the molecular control of tooth development. Following promotion to Reader in 1991 he was recruited to his present Chair at the Dental Institute of Guy’s Hospital (later to merge with Kings College), where he established a new basic research department, the Department of Craniofacial Development. The department, of which he remains head, now consists of 14 academic research groups with over 70 research staff. In 2002 he became Director of Research for the Dental Institute and head of a new academic grouping of craniofacial development, orthodontics and microbiology.
He has published over 180 research papers and supervised over 30 PhD students. He receives funding from the MRC, BBSRC and Wellcome Trust and is currently holder of an MRC Programme grant. In 2001 having obtained seed funding to develop stem cell based approaches for tooth renewal, he founded a spin-out company which has recently raised its second round of funding. He basic research work continues to explore the genetic interactions that control tooth development. In 2004 he was awarded the Craniofacial Biology Research Award by the International Association for Dental Research in recognition of his contribution to the understanding of how teeth develop.
After graduation from the Faculty of Medicine, University of Tokyo in 1990, I started my career as an orthopaedic surgeon in the Tokyo University Hospital. After seven years of clinical experience focused on rheumatology, I began my research on the mechanism of bone destruction in arthritis in the Department of Orthopaedic Surgery and the Department of Immunology, University of Tokyo. I studied the interplay between RANKL and interferons in the regulation of osteoclastogenesis and also found that NFATc1 is a critical transcription factor for osteoclastogenesis.
In 2003, I began my own laboratory as a Professor in the Department of Cellular Physiological Chemistry, Tokyo Medical and Dental University and continued to explore the interdisciplinary field, osteoimmunology. In April 2005, I became a Professor of the Department of Cell Signaling, Tokyo Medical and Dental University.
David Torgerson is Director of the York Trials Unit and is a health economist by background. He has undertaken a number of economic evaluations for the prevention of osteoporosis. He also has undertaken several epidemiological studies looking at risk factors for fracture and is an investigator on a number of large randomised controlled trials evaluating fracture prevention strategies. He is an author on many original papers, reports and book chapters in the field of osteoporosis treatment and prevention.
Full professor and head of the Laboratory of Mineralized Tissues at
School of Medicine, University of Zagreb. Visiting scientist, Bone Cell
Biology Section and Laboratory of Developmental Biology and Anomalies,
NIH, Bethesda, MD.
Hans Westerhoff is active in various world-wide Systems
Andrew Wilkie was appointed as Nuffield Professor of Pathology at the University of Oxford in 2003 and is an Honorary Consultant in Clinical Genetics at the Oxford Radcliffe Hospitals NHS Trust. He trained in clinical and molecular genetics in Oxford, London and Cardiff before starting an independent research group, based at the Weatherall Institute of Molecular Medicine, Oxford, in 1993. His interests focus on the molecular genetic analysis of patients with craniofacial and limb malformations and the insights that these provide into processes of mutation and development. This has led to the identification of several human disease genes and a newly proposed mechanism of selfish mutation in the testis.
Meet the Professor
Allied Health Professionals Session